Skip to content
FacebookXLinkedInYouTube
  • Home
  • Contact Us
  • Member Login
  • Français
CASN Logo CASN Logo
  • About The Project
  • Modules
  • Case Studies
  • PCS Game
  • About CASN
  • Contact Us

module-menu-test

  1. Home
  2. Modules
  3. module-menu-test
module-menu-testMichael Foley2017-01-31T23:42:33+00:00
  • Modules
  • module-menu-test
  • Table of Contents
  • Resource Overview
  • Module 1
    • Lesson 2: 1/11- Learning Outcome
    • Lesson 2: 10/11 – Summary
    • Lesson 2: 11/11 – Learning Activities and Reflection
    • Lesson 2: 2/11 – Introduction
    • Lesson 2: 3/11 – Regulation of Nursing Practice in Canada
    • Lesson 2: 4/11 – Provincial and Territorial Regulatory Resources for CDS (1/2) _
    • Lesson 2: 5/11 – Provincial and Territorial Regulatory Resources for CDS (2/2)
    • Lesson 2: 6/11 – Maintenance of Professional Competence
    • Lesson 2: 7/11 – Learning activities for continuing competence related to CDS prescribing
    • Lesson 2: 8/11 – Protection of Personal Health Information
    • Lesson 2: 9/11 – Learning Activity concerning Protection of Personal Health Information
    • Lesson 3: 1/7 – Learning Outcome
    • Lesson 3: 2/7 – Introduction
    • Lesson 3: 3/7 – Prescription Monitoring Programs (1/2) __
    • Lesson 3: 4/7 – Prescription Monitoring Systems (2/2) __
    • Lesson 3: 5/7 – Prescription Monitoring Programs across Canada
    • Lesson 3: 6/7 – Summary
    • Lesson 3: 7/7 – Activities and Reflections
    • Lesson 4: 1/25 – Learning Outcome
    • Lesson 4: 10/25 – Documentation and Record Keeping Exercise
    • Lesson 4: 11/25 – Reporting of Adverse Events to Increase Prescription Safety
    • Lesson 4: 12/25 – Disposal of Unused or Expired Medications to Increase Safety
    • Lesson 4: 13/25 – Storage and Transportation of CDS Approach to Increase Safety
    • Lesson 4: 14/25 – Storage and Transportation of CDS Exercise
    • Lesson 4: 15/25 – Practice Toolkits to Increase Safety
    • Lesson 4: 16/25 – Addiction Risk Assessment Approach to Safety
    • Lesson 4: 17/25 – Pain Assessment Tools
    • Lesson 4: 18/25 – Treatment Agreements to Increase Prescription Safety
    • Lesson 4: 19/25 – Treatment Agreements Exercise
    • Lesson 4: 2/25 – Introduction
    • Lesson 4: 20/25 – Urine Drug Testing to Increase Prescription Safety
    • Lesson 4: 21/25 – Urine Drug Testing Exercise
    • Lesson 4: 22/25 – Jurisdictional Pain Strategies Exercise
    • Lesson 4: 23/25 – Resources for Pain Management
    • Lesson 4: 24/25 – Summary
    • Lesson 4: 25/25 – Learning Activity and Reflection
    • Lesson 4: 3/25 – Drug Databases
    • Lesson 4: 4/25 – Health Canada Drug Product Database Exercise
    • Lesson 4: 5/25 – Safety Principles for Prescribing
    • Lesson 4: 6/25 – Application of Universal Precaution to Increase Safety
    • Lesson 4: 7/25 – Anti-drug strategy to increase safety
    • Lesson 4: 8/25 – Anti-drug exercise
    • Lesson 4: 9/25 – Record Keeping to Increase Prescription Safety
    • Lesson 5: 1/22 – Learning Outcome
    • Lesson 5: 10/22 Step 4: Appraise/Critique
    • Lesson 5: 11/22 – Step 5: Synthesize
    • Lesson 5: 12/22 – About Clinical Practice Guidelines (CPGs)
    • Lesson 5: 13/22 – Definition of Clinical Practice Guidelines (CPGs)
    • Lesson 5: 14/22 – Quality of Clinical Practice Guidelines (CPGs)
    • Lesson 5: 15/22 – Using CPGs in Practice
    • Lesson 5: 16/22 – Guideline Development
    • Lesson 5: 17/22 – Critical Appraisal of Clinical Practice Guidelines (CPGs): Key Components
    • Lesson 5: 18/22 – Case Study – Laureen’s Story
    • Lesson 5: 19/22 – Laureen – A Case Study Learning Activity
    • Lesson 5: 2/22 – Introduction
    • Lesson 5: 20/22 – Exercise
    • Lesson 5: 21/22 – Synthesizing and Applying the CPG to the Clinical Case Study
    • Lesson 5: 22/22 – Summary
    • Lesson 5: 3/22 – The evolving journey from Evidence-BASED practice to Evidence-INFORMED practice
    • Lesson 5: 4/22 – Evidence-BASED practice to Evidence-INFORMED practice
    • Lesson 5: 5/22 – Types of Credible Research and the Uniqueness of Substance Abuse and Misuse Evidence
    • Lesson 5: 6/22 – Steps to Evidence-informed Practice
    • Lesson 5: 7/22 – Step 1: Define
    • Lesson 5: 8/22 – Step 2: Search
    • Lesson 5: 9/22 – Step 3: Verify Credibility
    • Lesson 6: 1/23 – Learning Outcomes
    • Lesson 6: 10/23 – Application of The Four Topic Approach in CDS Prescribing
    • Lesson 6: 11/23 – Principles of The Four Topic Approach
    • Lesson 6: 12/23 – Reading
    • Lesson 6: 13/23 – Four Topics Approach to Clinical Ethics
    • Lesson 6: 14/23 – Application of the Four Topic Framework
    • Lesson 6: 15/23 – Medical Indications
    • Lesson 6: 16/23 – Treatment Collaboration
    • Lesson 6: 17/23 – Patient Preferences
    • Lesson 6: 18/23 – Respecting Patient Autonomy
    • Lesson 6: 19/23 – Quality of Life
    • Lesson 6: 2/23 – The Story of SM
    • Lesson 6: 20/23 – Contextual Features
    • Lesson 6: 21/23 – After the four topics
    • Lesson 6: 22/23 – Resolution of the Four Topics Approach
    • Lesson 6: 23/23 – Summary
    • Lesson 6: 3/23 – Introduction
    • Lesson 6: 4/23 – Learning Activity – Ethical Considerations related to CDS
    • Lesson 6: 5/23 – Reflective Questions
    • Lesson 6: 6/23 – Moral Values
    • Lesson 6: 7/23 – Exercise: Truth or Myth?
    • Lesson 6: 8/23 – Stigma Exercise
    • Lesson 6: 9/23 – Clinical Ethics: The Four Topic Approach
    • Module 1 – Introduction
    • Module 1 – Lesson 1 – Appendix B
    • Module 1 – Lesson 5 – Appendix A
    • Module 1 – Learning Outcomes
    • Modules intro
    • Lesson 1 – 1/15 – Learning Outcome
    • Lesson 1 – 2/15 – Federal Legislation and Regulation
    • Lesson 1: 3/15 – The Controlled Drugs and Substances Act (1/3) __
    • Lesson 1: 13/15 – Provincial Legislation and Regulations (2/2) __
    • Lesson 1: 4/15 – The Controlled Drugs and Substances Act (2/3) __
    • Lesson 1: 5/15 – The Controlled Drugs and Substances Act (3/3) __
    • Lesson 1: 6/15 – The New Classes of Practitioners Regulations (1/3) __
    • Lesson 1: 7/15 – The New Classes of Practitioners Regulations (2/3) __
    • Lesson 1: 8/15 – The New Classes of Practitioners Regulations (3/3) __
    • Lesson 1: 9/15 The Narcotic Control Regulations
    • Lesson 1: 10/15 The Benzodiazepines and Other Targeted Substances Regulations (BOTSR)
    • Lesson 1: 11/15 – The Food and Drug Regulations
    • Lesson 1: 12/15 – Provincial Legislation and Regulations (1/2) __
    • Lesson 1: 14/15 – Summary
    • Lesson 1: 15/15 – Learning Activities and Reflection
  • Module 2
    • Lesson 1: 1/44 – Learning Outcome
    • Lesson 1: 10/44 – Pharmacokinetics of Opioids
    • Lesson 1: 11/44 – Opioids – Common indications and dosages (1/2) __
    • Lesson 1: 12/44 – Opioids – Common Indications and Dosages (2/2) _
    • Lesson 1: 13/44 – Opioids – General Approaches to Management
    • Lesson 1: 14/44 – Opioids – Common adverse effects
    • Lesson 1: 15/44 – Opioids – Contraindications/Precautions
    • Lesson 1: 16/44 – Benzodiazepines
    • Lesson 1: 17/44 – Benzodiazepines – Pharmacodynamics
    • Lesson 1: 18/44 – Benzodiazepines – Pharmacokinetics (1/2) _
    • Lesson 1: 19/44 – BENZODIAZEPINES – Pharmacokinetics (2/2) _
    • Lesson 1: 2/44 – Introduction
    • Lesson 1: 20/44 – Benzodiazepines – Common Indications and Dosages
    • Lesson 1: 21/44 – Benzodiazepines – General Approaches to Management
    • Lesson 1: 22/44 – Benzodiazepines – Common adverse effects
    • Lesson 1: 23/44 – Benzodiazepines – Precautions
    • Lesson 1: 24/44 – BARBITURATES
    • Lesson 1: 25/44 – Barbiturates – Pharmacodynamics / mechanism of action
    • Lesson 1: 26/44 – Barbiturates – Pharmacokinetics (1/2) _
    • Lesson 1: 27/44 – Barbiturates – Pharmacokinetics (2/2) _
    • Lesson 1: 28/44 – Barbiturates – Indications (1/2) _
    • Lesson 1: 29/44 – Barbiturates – Indications (2/2) _
    • Lesson 1: 3/44 – Some Basic Definitions (1/2) _
    • Lesson 1: 30/44 – Barbiturates – Common adverse effects
    • Lesson 1: 31/44 – Barbiturates – Precautions
    • Lesson 1: 32/44 – Psychostimulants / amphetamines
    • Lesson 1: 33/44 – Psychostimulants/amphetamines – Pharmacodynamics
    • Lesson 1: 34/44 – Psychostimulants / amphetamines – Pharmacokinetics (1/2) _
    • Lesson 1: 35/44 – Psychostimulants / amphetamines – Pharmacokinetics (2/2) _
    • Lesson 1: 36/44 – Psychostimulants / amphetamines – Indications (1/2) _
    • Lesson 1: 37/44 – Psychostimulants/amphetamines – Indications (2/2) _
    • Lesson 1: 38/44 – Psychostimulants/amphetamines – Common adverse effects
    • Lesson 1: 39/44 – Anabolic steroids
    • Lesson 1: 4/44 – Some Basic Definitions (2/2) __
    • Lesson 1: 40/44 – Anabolic steroids – Pharmacodynamics/mechanism of action
    • Lesson 1: 41/44 – Anabolic steroids – Pharmacokinetics
    • Lesson 1: 42/44 – Anabolic steroids – Indications and dosage
    • Lesson 1: 43/44 – Anabolic steroids – Precautions
    • Lesson 1: 44/44 – Summary
    • Lesson 1: 5/44 – Learning Activity
    • Lesson 1: 6/44 – Opioids
    • Lesson 1: 7/44 – Opioids – Pharmacodynamics (1/2) _
    • Lesson 1: 8/44 -Opioids – Pharmacodynamics (2/2) __
    • Lesson 1: 9/44 – Opioids – Pharmacokinetics
    • Lesson 2: 1/18 – Learning Outcome
    • Lesson 2: 10/18 – Buprenorphine and buprenorphine/naloxone (3/3) __
    • Lesson 2: 11/18 – Cannabinoids
    • Lesson 2: 12/18 – Cannabinoids – Regulatory Considerations for Prescribing
    • Lesson 2: 13/18 – Cannabinoids – Pharmacodynamics/mechanism of action
    • Lesson 2: 14/18 – Cannabinoids – Pharmacokinetics
    • Lesson 2: 15/18 – Cannabinoids – Common indications and dosages
    • Lesson 2: 16/18 – Cannabinoids – Adverse reactions and management
    • Lesson 2: 17/18 – Cannabinoids – Precautions
    • Lesson 2: 18/18 – Cannabinoids – Learning activities
    • Lesson 2: 2/18 – Methadone
    • Lesson 2: 3/18 – Methadone – Special exemptions for prescribing
    • Lesson 2: 4/18 – Methadone – Pharmacodynamics / mechanism of action
    • Lesson 2: 5/18 – Methadone – Pharmacokinetics
    • Lesson 2: 6/18 – Methadone – Indications
    • Lesson 2: 7/18 – Methadone – Precautions
    • Lesson 2: 8/18 Buprenorphine and Buprenorphine/Naloxone (1/3) _
    • Lesson 2: 9/18 – Buprenorphine and buprenorphine/naloxone (2/3) __
    • Lesson 3: 1/5 – Learning Outcome
    • Lesson 3: 2/5 – Other agents – Z-drugs
    • Lesson 3: 3/5 – Other agents – Gabapentinoids
    • Lesson 3: 4/5 – Other agents – Tramadol
    • Lesson 3: 5/5 – Summary
    • Lesson 4: 1/9 – Learning Outcome
    • Lesson 4: 2/9 – Introduction
    • Lesson 4: 3/9 – Opioid Rotation
    • Lesson 4: 4/9 – Opioid Rotation – Oral Opioid Dosage Conversion Table
    • Lesson 4: 5/9 – Opioid Rotation – Opioid Equivalency Calculators
    • Lesson 4: 6/9 – Opioid Rotation – Learning Activities
    • Lesson 4: 7/9 – Adjusting Benzodiazepine Doses
    • Lesson 4: 8/9 – Creating a Safe Environment for Prescribing
    • Lesson 4: 9/9 – Summary
    • Lesson 5: 1/9 – Learning Outcome
    • Lesson 5: 2/9 – Introduction
    • Lesson 5: 3/9 – Psychosocial Influences (1/2) _
    • Lesson 5: 4/9 – Psychosocial Influences (2/2) _
    • Lesson 5: 5/9 – Cultural and ethnic variables
    • Lesson 5: 6/9 – Genetic Influences
    • Lesson 5: 7/9 – Gender influences
    • Lesson 5: 8/9 – Patient Teaching
    • Lesson 5: 9/9 – Summary
    • Module 2 – Learning Outcomes
    • Module 2 – Introduction
  • Module 3
    • Lesson 4: 1/8 – Learning Outcome
    • Module 3 – Introduction
    • Lesson 1: 1/12 – Learning Outcome
    • Lesson 1: 2/12 – Definition of Chronic Pain
    • Lesson 1: 3/12 – Epidemiology of chronic pain
    • Lesson 1: 4/12 – Chronic Pain: Need for Opioid Therapy
    • Lesson 1: 5/12 – Chronic Pain: Comprehensive Assessment (1/5) _
    • Lesson 1: 6/12 – Chronic Pain: Comprehensive Assessment (2/5) __
    • Lesson 1: 7/12 – Chronic Pain: Comprehensive Assessment (3/5) __
    • Lesson 1: 8/12 – Chronic Pain: Comprehensive Assessment (4/5) __
    • Lesson 1: 9/12 – Chronic Pain: Comprehensive Assessment (5/5) __
    • Lesson 1: 10/12 – Chronic Pain: Safety Considerations
    • Lesson 1: 11/12 – Chronic Pain: Goals of Care
    • Lesson 1: 12/12 – Summary
    • Lesson 2: 1/12 – Learning Outcome
    • Lesson 2: 2/12 – Epidemiology of Acute Pain
    • Lesson 2: 3/12– Acute Pain: Need for Opioid Therapy
    • Lesson 2: 4/12 – Acute Pain: Comprehensive Assessment (1/5) __
    • Lesson 2: 5/12 – Acute Pain: Comprehensive Assessment (2/5) __
    • Lesson 2: 6/12 – Acute Pain: Comprehensive Assessment (3/5) __
    • Lesson 2: 7/12 – Acute Pain: Comprehensive Pain Assessment (4/5) __
    • Lesson 2: 8/12 – Acute Pain: Comprehensive Assessment (5/5) __
    • Lesson 2: 9/12 – Acute Pain: Safety Considerations
    • Lesson 2: 10/12 – Acute Pain: Goals of Care
    • Lesson 2: 11/12 – Comprehensive Assessment of Acute Pain in Children
    • Lesson 2: 12/12 – Comprehensive Assessment of Acute Pain in Older Adults
    • Lesson 3: 1/7 – Learning Outcome
    • Lesson 3: 2/7 – Definition of Insomnia
    • Lesson 3: 3/7 – Insomnia: Symptom Assessment
    • Lesson 3: 4/7 – Physical Examination
    • Lesson 3: 5/7 – Standard Assessment Tools
    • Lesson 3: 6/7 – Safety Considerations
    • Lesson 3: 7/7 – Goals of Care
    • Lesson 4: 2/8 – Epidemiology of ADHD
    • Lesson 4: 3/8 – ADHD: Comprehensive Assessment (1/4) __
    • Lesson 4: 4/8 – ADHD: Comprehensive Assessment (2/4) __
    • Lesson 4: 5/8 ADHD: Comprehensive Assessment (3/4) __
    • Lesson 4: 6/8 – ADHD: Comprehensive Assessment (4/4) __
    • Lesson 4: 7/8 – ADHD: Safety Considerations
    • Lesson 4: 8/8 – ADHD: Goals of Care
    • Lesson 5: 1/13 – Learning Outcome
    • Lesson 5: 2/13 – Symptoms of Anxiety
    • Lesson 5: 3/13 – Anxiety Disorders
    • Lesson 5: 4/13 – Assessment, Diagnosis, and Management of Anxiety
    • Lesson 5: 5/13 – Epidemiology of Anxiety Disorders
    • Lesson 5: 6/13 – Anxiety: Need for CDS & Comprehensive Assessment (1/5) __
    • Lesson 5: 7/13 – Anxiety: Comprehensive Assessment (2/5) __
    • Lesson 5: 8/13 – Anxiety: Comprehensive Assessment (3/5) __
    • Lesson 5: 10/13 – Anxiety: Comprehensive Assessment (5/5) __
    • Lesson 5: 9/13 – Anxiety: Comprehensive Assessment (4/5) __
    • Lesson 5: 11/13 – Anxiety: Safety Considerations
    • Lesson 5: 12/13 – Anxiety: Goals of Care
    • Lesson 5: 13/13 – Other Considerations: Post-Traumatic Stress Disorder (PTSD)
    • Lesson 6: 1/6 – Learning Outcome
    • Lesson 6: 2/6 – Epidemiology of Status Epilepticus
    • Lesson 6: 3/6 – Status Epilepticus: Comprehensive Assessment (1/2) __
    • Lesson 6: 4/6 – Status Epilepticus: Comprehensive Assessment (2/2) __
    • Lesson 6: 5/6 – Status Epilepticus: Safety Considerations
    • Lesson 6: 6/6 – Status Epilepticus: Goals of Care
  • Module 4
    • Lesson 2: 10/13 — Equianalgesia
    • Lesson 2: 11/13 — Pediatric dosing of opioids
    • Lesson 2: 12/13 — Choose the correct opioid formulation
    • Lesson 2: 8/13 — Prescribing opioids (2/3) __
    • Lesson 2: 9/13 — Prescribing opioids (3/3) __
    • Lesson 4: 3/12 – Opioid tapering (2/3) __
    • Lesson 4: 4/12 – Opioid tapering (3/3) __
    • Module 4 – Introduction
    • Lesson 1: 1/7 — Learning Outcome
    • Lesson 1: 2/7 — Need for judicious CDS prescribing (1/5) __
    • Lesson 1: 3/7 — Need for judicious CDS prescribing (2/5) __
    • Lesson 1: 4/7 — Need for judicious CDS prescribing (3/5) __
    • Lesson 1: 5/7 — Need for judicious CDS prescribing (4/5) __
    • Lesson 1: 6/7 — Awareness of drug plan limits and exceptional access programs
    • Lesson 1: 7/7 — Need for judicious CDS prescribing (5/5) __
    • Lesson 2: 1/13 — Learning Outcome
    • Lesson 2: 2/13 — Prescribing competency: self-assessment
    • Lesson 2: 3/13 — Prior to CDS prescribing
    • Lesson 2: 4/13 — Treatment agreements
    • Lesson 2: 6/13 — Choosing the right medication and dose
    • Lesson 2: 5/13 — Treatment agreement exercise
    • Lesson 2: 7/13 — Prescribing opioids (1/3) __
    • Lesson 2: 13/13 — Documents to review prior to prescribing an opioid
    • Lesson 3: 1/4 — Learning Outcome
    • Lesson 3: 2/4 – Outpatient prescriptions
    • Lesson 3: 3/4 – In-patient prescriptions
    • Lesson 3: 4/4 – Additional considerations
    • Lesson 4: 1/12 — Learning Outcome
    • Lesson 4: 2/12 – Opioid tapering (1/3) __
    • Lesson 4: 5/12 – Benzodiazepines (1/3) __
    • Lesson 4: 6/12 – Benzodiazepines (2/3) __
    • Lesson 4: 7/12 — Benzodiazepines (3/3) __
    • Lesson 4: 8/12 – Benzodiazepine rotation and tapering (1/2) __
    • Lesson 4: 9/12 – Benzodiazepines rotating and tapering (2/2) __
    • Lesson 4: 10/12 – Stimulants
    • Lesson 4: 11/12 – Rotation and tapering of stimulant medications
    • Lesson 4: 12/12 – Summary
  • Module 5
    • Lesson 3: 3/3 – Focused history and physical
    • Lesson 4: 2/5 – Responding to prescription fraud
    • Lesson 4: 3/5 – Prescription theft
    • Module 5 – Introduction
    • Lesson 1: 1/2 – Learning Outcome
    • Lesson 1: 1/2 – Treatment evalution
    • Lesson 2: 1/3 – Learning Outcome
    • Lesson 2: 2/3 – Aberrant drug-related behaviour (1/2) __
    • Lesson 2: 3/3 – Aberrant drug-related behaviour (2/2) __
    • Lesson 3: 1/3 – Learning Outcome
    • Lesson 3: 2/3 – Follow up activities
    • Lesson 4: 1/5 – Learning Outcome
    • Lesson 4: 4/5 – Referrals
    • Lesson 4: 5/5 – Learning activities and reflection

Subscribe

Subscribe to our newsletter to get the latest feeds

Thank-you

Contact Us

1145 Hunt Club Road, Unit 450
Ottawa, ON, K1V 0Y3
Tel: (613) 235-3150
Fax: (613) 235-4476
© Canadian Association of Schools of Nursing / Association canadienne des écoles de sciences infirmières
All Rights Reserved | Developed by Member365
FacebookXLinkedInYouTube
Page load link
Go to Top